Cargando…

Prevalence of phenotypes of acute respiratory distress syndrome in critically ill patients with COVID-19: a prospective observational study

BACKGROUND: In acute respiratory distress syndrome (ARDS) unrelated to COVID-19, two phenotypes, based on the severity of systemic inflammation (hyperinflammatory and hypoinflammatory), have been described. The hyperinflammatory phenotype is known to be associated with increased multiorgan failure a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sinha, Pratik, Calfee, Carolyn S, Cherian, Shiney, Brealey, David, Cutler, Sean, King, Charles, Killick, Charlotte, Richards, Owen, Cheema, Yusuf, Bailey, Catherine, Reddy, Kiran, Delucchi, Kevin L, Shankar-Hari, Manu, Gordon, Anthony C, Shyamsundar, Murali, O'Kane, Cecilia M, McAuley, Daniel F, Szakmany, Tamas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2020
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7718296/ https://www.ncbi.nlm.nih.gov/pubmed/32861275 http://dx.doi.org/10.1016/S2213-2600(20)30366-0

Ejemplares similares

Comparison of machine learning clustering algorithms for detecting heterogeneity of treatment effect in acute respiratory distress syndrome: A secondary analysis of three randomised controlled trials
por: Sinha, Pratik, et al.
Publicado: (2021)

Simvastatin decreases the level of heparin-binding protein in patients with acute lung injury
por: McAuley, Daniel F, et al.
Publicado: (2013)

Heterogeneity of treatment effect by baseline risk of mortality in critically ill patients: re-analysis of three recent sepsis and ARDS randomised controlled trials
por: Santhakumaran, Shalini, et al.
Publicado: (2019)

Procalcitonin Increase Is Associated with the Development of Critical Care-Acquired Infections in COVID-19 ARDS
por: Richards, Owen, et al.
Publicado: (2021)

Mesenchymal stromal cell extracellular vesicles rescue mitochondrial dysfunction and improve barrier integrity in clinically relevant models of ARDS
por: Dutra Silva, Johnatas, et al.
Publicado: (2021)

Prevention of post-operative complications by using a HMG-CoA reductase inhibitor in patients undergoing one-lung ventilation for non-cardiac surgery: study protocol for a randomised controlled trial
por: Shyamsundar, Murali, et al.
Publicado: (2018)

KL-6 in acute lung injury: will it leave its mark?
por: Shyamsundar, Murali, et al.
Publicado: (2008)

Aspirin as a potential treatment in sepsis or acute respiratory distress syndrome
por: Toner, Philip, et al.
Publicado: (2015)

Baseline plasma IL-18 may predict simvastatin treatment response in patients with ARDS: a secondary analysis of the HARP-2 randomised clinical trial
por: Boyle, Andrew James, et al.
Publicado: (2022)

Differences in Inflammatory Marker Kinetics between the First and Second Wave of COVID-19 Patients Admitted to the ICU: A Retrospective, Single-Center Study
por: Szakmany, Tamas, et al.
Publicado: (2021)

Acute Respiratory Distress Syndrome Subphenotypes beyond the Syndrome: A Step toward Treatable Traits?
por: Reddy, Kiran, et al.
Publicado: (2021)

Delirium in COVID-19: can we make the unknowns knowns?
por: Wilcox, M. Elizabeth, et al.
Publicado: (2021)

Towards a biological definition of ARDS: are treatable traits the solution?
por: Bos, Lieuwe D. J., et al.
Publicado: (2022)

Comparing regression and neural network techniques for personalized predictive analytics to promote lung protective ventilation in Intensive Care Units
por: Hagan, Rachael, et al.
Publicado: (2020)

The relationship between plasma cystatin C, mortality and acute respiratory distress syndrome subphenotype in the HARP-2 trial
por: McKelvey, Michael C., et al.
Publicado: (2023)

Evidence for chemokine synergy during neutrophil migration in ARDS
por: Williams, Andrew E, et al.
Publicado: (2017)

The interaction between arterial oxygenation and carbon dioxide and hospital mortality following out of hospital cardiac arrest: a cohort study
por: McGuigan, Peter J., et al.
Publicado: (2020)

Hypercapnic acidosis induces mitochondrial dysfunction and impairs the ability of mesenchymal stem cells to promote distal lung epithelial repair
por: Fergie, Nicola, et al.
Publicado: (2019)

0995. Aspirin reduces neutrophilic pulmonary inflammation in a human model of acute respiratory distress syndrome induced by inhaled lipopolysaccharide
por: Hamid, U Imran, et al.
Publicado: (2014)

Peeking under the Hood of Acute Respiratory Distress Syndrome Phenotypes: Deeper Insights into Biological Heterogeneity
por: Sinha, Pratik, et al.
Publicado: (2019)

Immunotherapy in COVID-19: why, who, and when?
por: Sinha, Pratik, et al.
Publicado: (2021)

Statin therapy in critical illness: an international survey of intensive care physicians’ opinions, attitudes and practice
por: Shankar-Hari, Manu, et al.
Publicado: (2012)

Keratinocyte growth factor in acute lung injury to reduce pulmonary dysfunction – a randomised placebo-controlled trial (KARE): study protocol
por: Cross, Laurence JM, et al.
Publicado: (2013)

Mucoactive agent use in adult UK Critical Care Units: a survey of health care professionals’ perception, pharmacists’ description of practice, and point prevalence of mucoactive use in invasively mechanically ventilated patients
por: Borthwick, Mark, et al.
Publicado: (2020)

A randomized clinical trial of ascorbic acid in open abdominal aortic aneurysm repair
por: Duffy, Martin J, et al.
Publicado: (2015)

Erratum to: Keratinocyte growth factor in acute lung injury to reduce pulmonary dysfunction – a randomised placebo-controlled trial (KARE): study protocol
por: Cross, Laurence J. M., et al.
Publicado: (2017)

Subphenotypes Assigned to Pediatric Acute Respiratory Failure Patients Show Differing Outcomes
por: Flori, Heidi R., et al.
Publicado: (2023)

A Porcine Ex Vivo Lung Perfusion Model To Investigate Bacterial Pathogenesis
por: Dumigan, Amy, et al.
Publicado: (2019)

Simvastatin for patients with acute respiratory distress syndrome: long-term outcomes and cost-effectiveness from a randomised controlled trial
por: Agus, A., et al.
Publicado: (2017)

Type XVIII collagen degradation products in acute lung injury
por: Perkins, Gavin D, et al.
Publicado: (2009)

The attributable mortality of acute respiratory distress syndrome
por: Auriemma, Catherine L., et al.
Publicado: (2020)

Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration in COVID-19 (REALIST-COVID-19): A structured summary of a study protocol for a randomised, controlled trial
por: Gorman, Ellen, et al.
Publicado: (2020)

Repair of acute respiratory distress syndrome by stromal cell administration (REALIST): a structured study protocol for an open-label dose-escalation phase 1 trial followed by a randomised, triple-blind, allocation concealed, placebo-controlled phase 2 trial
por: Gorman, Ellen, et al.
Publicado: (2022)

Cytokine adsorption during ECMO for COVID-19-related ARDS
por: Shekar, Kiran, et al.
Publicado: (2021)

Galectin-3 Inhibition in COVID-19
por: Reddy, Kiran, et al.
Publicado: (2022)

Hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in Acute lung injury to Reduce Pulmonary dysfunction (HARP-2) trial: study protocol for a randomized controlled trial
por: McAuley, Daniel F, et al.
Publicado: (2012)

Mitochondrial Transfer via Tunneling Nanotubes is an Important Mechanism by Which Mesenchymal Stem Cells Enhance Macrophage Phagocytosis in the In Vitro and In Vivo Models of ARDS
por: Jackson, Megan V., et al.
Publicado: (2016)

Hyperoxaemia and hypoxaemia are associated with harm in patients with ARDS
por: Boyle, Andrew J., et al.
Publicado: (2021)

Comparison of thermodilution measured extravascular lung water with chest radiographic assessment of pulmonary oedema in patients with acute lung injury
por: Brown, Lisa M, et al.
Publicado: (2013)

Repair of acute respiratory distress syndrome by stromal cell administration (REALIST) trial: A phase 1 trial
por: Gorman, Ellen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4t0kt0r682jdj9f65venk5e8n2